Portal de Periódicos da CAPES

Paradoxical oncogenesis: are all BRAF inhibitors equal?

2013; Wiley; Volume: 26; Issue: 5 Linguagem: Inglês

10.1111/pcmr.12132

1755-148X

Alexander M. Menzies, Richard Kefford, Georgina V. Long,

Cutaneous Melanoma Detection and Management

Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.